Shivalik Rasayan Ltd

Shivalik Rasayan Ltd

318.55
INR
+4.55
(+1.45%)
12.46EPS
27.32P/E
3.73BMarket Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
48.3
128.5
144.33
147.47
148.13
135.13
141.89
146.43
161.49
178.37
196.54
229.6
237.86
Basic EPS, GAAP
2.11
3.68
6.39
8.63
11.82
10.16
12.77
18.12
14.32
8.35
10.6
7.87
8.67
Free Cash Flow per Basic Share
3.55
11.19
6.07
-21.02
-31.79
-61.38
-4.71
-9.79
-56.72
-49.75
-20.22
-32.16
- -
Dividend per Share
- -
- -
- -
1.38
0.46
1.49
0.68
0.49
1.37
1.32
1.3
1.36
- -
Book Value per Share
13.15
16.5
12.62
46.48
119.95
127.93
129.96
198.21
214.01
250.41
263.57
279.58
- -
Tangible Book Value per Share
13.15
16.46
12.59
46.18
119.71
127.74
129.81
197.96
213.39
249.83
263.1
279.22
- -
Basic Weighted Avg Shares
9
9
9
11
12
14
14
14
14
15
16
16
16
Sales/Revenue/Turnover
413
1,099
1,234
1,551
1,705
1,863
1,956
2,070
2,340
2,715
3,096
3,616
3,750
Operating Margin (%)
6.43
7.62
13.06
14.03
12.2
13.91
16.32
18.98
14.13
10.98
8.12
7.99
7.36
Depreciation Expense
2
23
23
24
-1
35
86
110
116
46
156
188
184
Net Income, GAAP
18
32
55
91
136
140
176
256
207
127
167
124
137
Effective Tax Rate (%)
33.66
32.99
25.15
24.78
19.99
17.42
14.74
7.31
5.78
22.13
11.88
16.33
14.52
Profit Margin (%)
4.38
2.87
4.43
5.85
7.98
7.52
9
12.37
8.87
4.68
5.39
3.43
3.64
Working Capital
31
-15
85
574
1,503
829
400
1,267
1,180
1,355
1,364
1,919
- -
LT Debt
2
113
116
66
54
26
111
84
130
240
165
262
- -
Total Equity
112
154
263
944
2,197
2,495
2,595
3,647
4,193
5,076
5,362
5,991
- -
Return on Invested Capital (%)
- -
11.37
16.59
18.7
9.29
8.38
9.12
9.39
6.53
3.99
3.52
3.42
- -
Return on Capital (%)
- -
20.6
11.96
6.54
4.44
2.87
4.31
5.54
3.54
2.46
3.19
2.18
- -
Return on Common Equity (%)
- -
24.86
43.91
30.43
12.71
8.2
9.91
10.98
6.95
3.63
4.15
2.92
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
966
- -
LT Borrowings
- -
262
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
5,537
3,451
3,730

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,821
- -
Cash, Cash Equivalents & STI
- -
344
- -
Accounts Receivable, Net
- -
1,151
- -
Inventories
- -
1,469
- -
Total Current Liabilities
- -
1,902
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
966
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
57.39%
18.79%
11.72%
Free Cash Flow
13.25%
120.09%
59.08%
Net Income, GAAP
21.15%
-1.33%
-25.73%
Sales/Revenue/Turnover
12.79%
13.15%
16.82%
Total Cash Common Dividend
- -
33.99%
4.6%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
746
824
853
694
3,096
2026
893
938
820
1,028
3,616
2027
963
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.27
2.58
3.39
2.62
10.6
2026
1.02
1.93
1.71
2.87
7.87
2027
2.16
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.3
2026
- -
- -
- -
- -
1.36
2027
- -
- -
- -
- -
- -

Company Description

CEO
Vimal Kumar Shrawat
Full Time Employees
432
Sector
Process industries
Industry
Chemicals: agricultural
Address
1506, Chiranjiv Tower New Delhi DE India 110019
IPO Date
May 22, 2015
Business
Shivalik Rasayan Limited is an Indian manufacturer specializing in organophosphorus-based agrochemicals and active pharmaceutical ingredients (API). The company produces a range of products including Dimethoate Technical, Malathion Technical, and other organophosphorus insecticides and chemicals that are used for plant protection. Its pharmaceutical segment focuses on the development and production of oncology and non-oncology APIs as well as finished dosage forms. The company operates primarily in India with a growing presence in international markets including Africa, Latin America, Far-East and CIS countries through its subsidiary Medicamen Biotech Limited. Founded in 1979 and headquartered in New Delhi, Shivalik Rasayan has recently expanded its capabilities by acquiring Medicamen Biotech Limited, establishing a state-of-the-art R&D center recognized by the Government of India for API development, and setting up a new agrochemical and synthetic organic chemicals plant at Dahej, which is expected to be operational by 2023. These strategic moves signify a shift towards integrated pharmaceutical manufacturing alongside its well-established agrochemical portfolio. The company serves diverse customer segments across agriculture and healthcare industries, delivering high-quality technical chemicals and pharmaceutical ingredients. This description encapsulates Shivalik Rasayan Limited's core product offerings, recent strategic expansions including acquisitions and facility upgrades, industry focus, geographic reach, and foundational background.